Nicotine pouches and oral health

Last updated

What happens at the placement site

A nicotine pouch sits against the gum, usually in the upper lip vestibule near the canine or premolar teeth, for anywhere from a few minutes to an hour. During that time the tissue underneath is exposed to a sustained, concentrated dose of nicotine and the other ingredients described on /wiki/chemistry/, absorbed directly across the oral mucosa as covered on /wiki/oral-absorption/. That combination of prolonged contact, a fixed location, and a fibrous pouch material pressing on soft tissue is the starting point for everything researchers have found so far. Nicotine pouches are a recent product category — mass-market sales in the United States trace to around 2019 — so the evidence base is thin compared with tobacco smoking or Swedish snus, and most of what exists is small, short-term, or borrowed from those older products. This page summarizes what has actually been studied, distinguishes pouch-specific findings from extrapolated evidence, and states plainly where the evidence stops.

Mucosal lesions at the placement site

The most consistently documented finding in nicotine pouch users is a visible change to the mucosa exactly where the pouch is placed. A 2024 case series in Diagnostic Pathology examined five daily users and found white lesions at the placement site in all of them — ranging from thin linear streaks to denser, cloud-like or leathery patches — on the gingiva, frenulum, buccal mucosa, and vestibulum under the upper lip. Biopsies showed parakeratosis (a thickened, whitened surface layer), acanthosis (epithelial thickening), tissue swelling, dilated capillaries, and a mild chronic inflammatory infiltrate (Miluna-Meldere et al., 2024). These changes closely resemble the mucosal lesions long described in Swedish snus users, where a 2025 narrative review in Cureus reports that roughly 79% of daily snus users show some placement-site mucosal alteration (Bogdanska et al., 2025) — snus evidence, not pouch evidence, and it matters that snus contains tobacco leaf while pouches do not.

There is one piece of pouch-specific longitudinal data. A study tracking users who switched from Swedish snus to a nicotine pouch found that reversible histological mucosal changes had normalized by the first follow-up visit, two to six weeks later, once tobacco leaf exposure stopped (Scherer, Pluym & Scherer, 2024). A separate five-week pilot study of 23 Swedish dentists who switched exclusively to one pouch brand with a barrier layer found self-reported lesion prevalence fell from 95.7% to 69.6%, and moderate-to-severe lesions dropped from 39.1% to zero (La Rosa, Fagerström et al., 2025). That study had no control group, ran for only five weeks, relied on self-report, and was conducted with product donated by the manufacturer; its co-author Karl Fagerström is a paid consultant to Swedish Match and founded the company that created the first non-tobacco nicotine pouch, a closer industry tie than "consulting ties" conveys — reasons to treat the specific numbers as preliminary rather than definitive, even though the direction (fewer lesions without tobacco leaf) fits the mechanistic picture.

The 2024 review covering emerging oral nicotine products found only three studies of non-cigarette nicotine products in total, and only two that looked at oral nicotine pouches specifically. Its authors state plainly that there is not enough published data to draw firm conclusions about pouch-specific effects on gum recession, periodontal disease progression, dry mouth, or cavities (Scherer, Pluym & Scherer, 2024).

Gum recession

Two clinical case reports published in 2025 describe young, otherwise healthy daily pouch users — 11 and 18 months of use — who developed localized gum recession precisely at the spot where they habitually placed pouches, with no recession elsewhere in the mouth; the shorter-duration case also showed a whitish leukoplakia patch at the same site. Periodontal charting and radiographs in both cases ruled out generalized gum disease, teeth grinding, or aggressive brushing as the cause, pointing to the pouch placement itself as the likely local irritant (Alkhatib, 2025). Two case reports cannot establish how common this is, only that it can happen. A fuller discussion, including what the mechanism might be and how this compares with tobacco-containing products, is on /wiki/gum-recession/.

Gum disease (gingivitis and periodontitis)

Gingivitis — reversible gum inflammation and bleeding — and periodontitis — the deeper, potentially irreversible loss of the bone and ligament that anchor a tooth — are different conditions, and the pouch evidence for each is different. A 2023 review in the International Journal of Dentistry lays out plausible biological mechanisms by which nicotine itself, independent of smoke, could affect the gums: activating nicotinic receptors on gum cells, suppressing ligament fibroblasts, raising inflammatory signaling, and disrupting the oral microbiome (Ye & Rahman, 2023). This is a mechanistic argument, not a clinical trial in pouch users. In the five-week pilot study above, self-reported gingivitis cases dropped to zero and gingival irritation fell by roughly 90% after switching to a barrier-style pouch — but the same study found gum recession, once present, did not reverse over the five-week period (La Rosa, Fagerström et al., 2025), consistent with recession being structural damage rather than active inflammation. The case series noted above deliberately excluded anyone with a periodontal screening score indicating active disease, so it cannot speak to periodontitis rates (Miluna-Meldere et al., 2024). A longer discussion of the gingivitis/periodontitis distinction and the mechanistic evidence is on /wiki/gum-disease/.

Nicotine's known effects on gum tissue and blood flow

Independent of any specific product, nicotine has measurable biological effects on periodontal tissue that predate pouches by decades and come mostly from smoking and nicotine-replacement research. Nicotine is a vasoconstrictor — it narrows blood vessels — and a 2010 review in the Journal of Indian Society of Periodontology found human studies genuinely mixed on whether this reduces gingival blood flow in smokers, since smoking also raises blood pressure in ways that can offset the constriction; the review is clearer that nicotine alters gum fibroblast attachment, reduces collagen production while increasing the enzyme that breaks collagen down, impairs neutrophil function, and slows bone healing after periodontal injury (Malhotra et al., 2010). A 2024 review of nicotine patches — a non-combustion, transdermal nicotine source with no oral placement at all — found broadly similar vasoconstriction and reduced-fibroblast-proliferation effects, but concluded these effects were markedly milder than those from smoking, and that patch users tend to see better periodontal healing than smokers largely because they avoid combustion byproducts entirely (Alayadi, 2024). None of this is pouch-specific evidence; it establishes only that nicotine itself is not biologically inert to gum tissue, which is a plausible mechanism for the localized findings in the case reports above rather than proof that pouches cause any particular outcome.

Dry mouth

The same nicotine patch review reports that nicotine can reduce salivary flow with sustained use, which in principle favors plaque buildup and cavities, but again describes the effect as generally mild relative to smoking (Alayadi, 2024). No study identified for this page has directly measured salivary flow in nicotine pouch users specifically; the mechanism is plausible by extension from nicotine pharmacology, not demonstrated in pouch users.

Tooth staining

Tobacco-leaf smokeless products such as chewing tobacco are well documented to stain teeth brown to black over time as tobacco compounds bind to dental surfaces (Bogdanska et al., 2025). Nicotine pouches contain no tobacco leaf, and no study identified for this page reports staining specific to pouch use. The absence of a pouch-specific staining study is not the same as evidence that staining does not occur; it means the question has not been directly tested.

How this compares with snus and with smoking

Smoking is the best-established risk factor in periodontal research: a review of the epidemiological and clinical literature describes smoking as consistently associated with both greater frequency and greater severity of periodontal disease, through nicotine-driven vasoconstriction (though, as noted above, direct measurements of gum blood flow in smokers are mixed), impaired immune cell function, and poorer oral hygiene among smokers generally (Turnbull, 1995). Smokeless tobacco use generally — snus, chewing tobacco, and related tobacco-leaf products, pooled across 19 studies — is associated with a roughly 1.7-fold higher odds of gum recession at the placement site and nearly three times the prevalence of periodontitis, with the risk not clearly tied to any one product type (Bogdanska et al., 2025). Nicotine pouches sit in a different category: no combustion, no tobacco leaf, but still direct, prolonged nicotine contact with a fixed patch of gum tissue. Where a pouch-switch study exists, mucosal lesions improved after leaving tobacco-containing snus, consistent with tobacco leaf — not nicotine alone — driving much of snus's mucosal damage (Scherer, Pluym & Scherer, 2024). Whether pouches carry a smaller, larger, or comparable long-term periodontal risk to snus has not been settled by direct study.

What remains unknown

No study identified for this page follows pouch users for more than a few weeks, uses a control group, or measures periodontitis (as opposed to gingivitis or surface lesions) as a primary outcome. The 2024 critical review covering oral nicotine pouches found essentially no published data on long-term periodontal disease progression, dry mouth, or cavity rates specific to pouch use, and explicitly could not evaluate any link to oral cancer for lack of suitable data (Scherer, Pluym & Scherer, 2024). The clinical case reports establish that localized gum recession and leukoplakia can occur at a pouch placement site in individual users; they do not establish how common this is across the broader user population, whether it is dose-dependent, or whether it reverses after quitting. Readers looking for cessation-focused resources rather than an evidence review can see /guides/overcome-nicotine-addiction/ and /guides/use-nicotine-pouches/; readers interested in the regulatory classification of these products can see /wiki/regulation/, and in the nicotine itself, /wiki/nicotine/.

Evidence reviewed 2026-08-19.

Sources